Patients Why “rare disease” is a regulatory label, not a patient real... Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
R&D Net Treatment Benefit in rare disease trials: Aligning trial... Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.
R&D Sponsored Webinar recap: The future of cell and gene therapy in rare d... For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of them
R&D On a journey to diverse, inclusive, and more efficient rare ... Although orphan drugs represent a sizeable portion of new drug approvals,1most rare diseases still lack effective treatment.
News Lilly partners with Hims & Hers on obesity drug sales Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
